Détail de l'éditeur
Documents disponibles chez cet éditeur (463)
Rapport
At the end of September 2012, the EMCDDA and Europol examined the available information on a new psychoactive substance 5-(2-aminopropyl)indole (commonly known by the abbreviation '5-IT'), through a joint assessment. The two organisations conclu[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the [...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the EMCDDA and[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the availabl[...]Rapport
In May 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), through a joint assessment. The two organisations[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PINACA, through a joint asses[...]Rapport
In February 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA, through a joint assessment.[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint [...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint asses[...]Rapport
In September 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, commonly known as acryloylfentanyl, through a joint assessment. The two organisations [...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide, commonly known as 4-fluoroisobutyrylfentanyl (4F-iBF), through a joint ass[...]Rapport
In September 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (acetylfentanyl), through a joint assessment. The two organisations concluded that[...]Rapport
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), through a joint assessment. The two organis[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran-2-carboxamide, commonly known as tetrahydrofuranylfentanyl (THF-F), through a [...]Rapport
Isotonitazene is a synthetic opioid analgesic monitored by the EMCDDA as a new psychoactive substance through the European Union Early Warning System since 2019. Based on potential public health risks, an initial report has been prepared and sub[...]Rapport
Rapport
These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 20[...]Rapport
This paper is part of the EMCDDA activity around the development and improvement of drug supply indicators, with a focus on drug-related homicide. It builds upon the 2017 review of the academic research and data sources on drug-related homicide [...]Rapport
This report is a rapid and preliminary analysis of the impact of COVID-19 on selected online markets. Three relatively large darknet markets were reviewed for the purposes of this study, selected because of their importance to the EU market and [...]Rapport
The protocol establishes harmonised criteria to extract process and report cases, based on the information available, at the end point of the chain of certification/ascertainment procedures, at different mortality registries: General Mortality R[...]Rapport
This report was compiled as a supporting document for the evaluation of the 2005-12 EU drugs strategy and its two action plans: 2005-08 and 2009-12. It reviews the main trends and changes in the European drug situation and in the responses devel[...]Rapport
Since the beginning of 2020, the world has been experiencing an unprecedented public health emergency caused by the coronavirus disease (COVID-19) pandemic, which has led to the progressive introduction of social distancing and other control mea[...]Rapport
FRANÇAIS : Depuis le début de l'année 2020, le monde connaît une situation sanitaire sans précédent causée par la pandémie de coronavirus (COVID-19), qui a conduit à l'introduction progressive de mesures de distanciation sociale et d'autres mes[...]Rapport
Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this outbreak for drug ser[...]Rapport
Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this pandemic for people w[...]Rapport
Brief interventions are psychosocial techniques designed to help recipients recognise harmful patterns of substance use, and to motivate and support them to address that use. Studies suggest that brief interventions in an emergency department ma[...]Périodique
OEDT = EMCDDA ; I. GIRAUDON ; G. MENA ; J. MATIAS ; J. VICENTE | Lisbon : OEDT / EMCDDA | Technical reports | 2014This study reveals the substantial levels of morbidity related to cocaine use, translated into the large number of cocaine cases seen in various emergency settings in European countries. This health burden is often not captured by other traditio[...]Rapport
OEDT = EMCDDA ; D. MANSFIELD ; A. CUNNINGHAM ; L. LANIEL ; P. GRIFFITHS ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Ad hoc publication | 2020This paper provides an analysis of the available data that suggest that a methamphetamine industry is rapidly being established in Afghanistan. The analysis provided is based on information from key informants, documentary sources and the analys[...]Rapport
Ce rapport tente de combler une partie du manque de connaissance sur le trafic, la consommation des drogues illicites et des médicaments psychotropes en Afrique. Il dresse un inventaire des organismes spécialisés intervenants dans le champ spéci[...]Rapport
The Netherlands and Belgium are known major producers of synthetic psychoactive drugs such as MDMA, amphetamine and, more recently, methamphetamine. The present study shows that as a result of the illicit production of these synthetic drugs, lar[...]Rapport
S. I. ONCIOIU ; G. BURKHART ; A. CALAFAT ; M. DUCH ; P. PERMAN-HOWE ; D. R. FOXCROFT | Lisbon : OEDT / EMCDDA | Technical reports | 2018Environmental prevention policies and interventions seek to limit opportunities for unhealthy or risky behaviour or promote the availability of healthier options in order to prevent problems associated with substance use. They do so by altering [...]Rapport
FRANÇAIS : Le Rapport ESPAD 2015 présente les expériences et les perceptions des élèves concernant diverses substances, comme le tabac, l'alcool, les drogues illicites, les produit à inhaler, les médicaments et les nouvelles substances psychoa[...]Rapport
FRANÇAIS : L'usage de tabac et d'alcool chez les élèves de 15 à 16 ans donne des signes de déclin, mais la consommation potentiellement problématique de cannabis et les difficultés posées par les nouvelles conduites addictives soulèvent des in[...]Rapport
This study estimates how much 22 European countries spent on drug-law offenders in prisons during the last decade. Based on this, an estimate for public expenditure on drug-law offenders at the European level was made.Rapport
M. QUIREYNS ; T. BOOGAERTS ; N. VAN WICHELEN ; A. COVACI ; A. L. N. VAN NUIJS | Lisbon : OEDT / EMCDDA | 2023Wastewater-based epidemiology (WBE) is proving to be a promising tool to back-estimate illicit drug market sizes. Within the framework of the Sewage analysis CORe group Europe (SCORE) network, influent wastewater (IWW) samples were analysed for [...]Rapport
This report presents estimates of aggregate market size for the different drugs at EU and European level and describes in detail how these estimates were achieved. Country level estimates are not reported given the uncertainty around some of the[...]Rapport
This report includes estimates of the total size of the retail drug market in the European Union in 2017 for cannabis, heroin, cocaine, amphetamines and MDMA.Rapport
OEDT = EMCDDA ; A. SARASA-RENEDO ; G. BARRIO ; L. MONTANARI ; B. GUARITA ; L. DE LA FUENTE ; M. J. BRAVO ; J. VICENTE | Lisbon : OEDT / EMCDDA | Technical reports | 2015FRANÇAIS : Ce rapport décrit les tendances en matière d'injection de drogues dans les États membres de l'UE, la Norvège et la Turquie entre 2000 et 2011, à travers une analyse des données relatives aux personnes recevant un traitement médicamen[...]Rapport
OEDT = EMCDDA, Organisateur de réunion ; Groupe Pompidou, Organisateur de réunion ; G. V. STIMSON ; A. JUDD ; P. D. A. COHEN ; P. LAZAROV ; R. SIMON ; C. MORENO IRIBAS ; M. URTIAGA DOMINGUEZ ; B. OLSSON ; P. GRIFFITHS ; M. FARRELL ; S. HOWES ; A. DOMINGO-SALVANY ; C. RICHARDSON ; P. Y. BELLO ; G. CHENE ; M. FRISCHER ; K. PÜSCHEL ; M. DAVOLI ; H. SAELAN ; C. TAYLOR ; D. J. KORF ; L. KRAUS ; W. KIRSCHNER ; Z. ELEKES ; J. SIEROSLAWSKI ; A. ZIELINSKI ; D. NOLIMAL ; R. HARTNOLL | Lisbon : OEDT / EMCDDA | Monographs, ISSN 1606-1691 | 1997FRANÇAIS : Cette monographie, qui présente la plupart des communications du séminaire "Addiction prevalence estimation: methods and research strategies", Strasbourg, juin 1996, est centrée sur la question : comment obtenir des estimations qui [...]Rapport
L'étude a révélé que l'information non-gouvernementale relative à la problématique évoquée était fortement sous-exploitée, principalement par manque de ressources techniques et d'appuis méthodologiques adaptés. Trois principes fondamentaux ont é[...]Document multimédia
"EU Drug Market: Amphetamine" describes the European amphetamine market from production and trafficking, to distribution and use. It details the processes, materials and actors involved at different stages and levels of the market. Taking a thre[...]Rapport
This resource offers a strategic and top-level summary for policymakers and decision-makers, to support the development and implementation of policies and actions in Europe, based on a robust understanding of the current drug landscape and emerg[...]Document multimédia
'EU Drug Market: Cannabis' describes the European cannabis market from production and trafficking, to distribution and use. It details the processes, materials and players involved at different stages and levels of the market. The module takes a[...]Rapport
Document multimédia
What are the latest changes in the EU opioids market? How are global geopolitical developments impacting supply? Are heroin trafficking routes changing? To what extent do synthetic opioids pose a threat to Europe? These are among the issues expl[...]Rapport
What effect is COVID-19 having on the drug market in the EU? This joint publication from the EMCDDA and Europol analyses the impact of the pandemic on the market for the main drug types (cannabis, heroin, cocaine, amphetamines, NPS), including d[...]Rapport
Rapport
The EU Drug Markets Report 2019 is the third comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol. The analysis presented in this report spans numerous topics such as the links between drugs and other cr[...]Rapport
FRANÇAIS : Le présent rapport analyse le phénomène du marché des drogues illicites dans le contexte plus large des nouvelles tendances en matière de consommation de drogue, des facteurs culturels et sociaux et des liens avec la criminalité. Les[...]Rapport
The EU drug markets report is the first comprehensive overview of illicit drug markets in the European Union. It covers issues such as production, consumer markets, trafficking, organised crime and policy responses, along with a review of the ma[...]